Testing new regimens in patients with advanced soft tissue sarcoma: Analysis of publications from the last 10 years

Annals of Oncology

Volumn 22, Issue 6, 2011, Pages 1266-1272

  Penel, N ^a,b   Van Glabbeke, M ^a   Marreaud, S ^a   Ouali, M ^a   Blay, J Y ^a,c   Hohenberger, P ^a,d  

^a EORTC DATA CENTER   (Belgium)

^b UNIV LILLE   (France)

^c UNIVERSITÉ LYON 1   (France)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Phase II trials; Second line regimens; Soft tissue sarcoma

Indexed keywords

6 O BENZYLGUANINE; ANTINEOPLASTIC AGENT; BIRICODAR; BORTEZOMIB; BROSTALLICIN; BRYOSTATIN; CARMUSTINE; DACARBAZINE; DOCETAXEL; DOLASTATIN; DOXORUBICIN; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IMATINIB; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; NAVELBINE; PACLITAXEL; PAZOPANIB; PERIFOSINE; RALTITREXED; ROSIGLITAZONE; SEMAXANIB; SOBLIDOTIN; SORAFENIB; SU 146; SU 416; TEMOZOLOMIDE; TOPOTECAN; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VZ 710;

ADVANCED CANCER; ANGIOSARCOMA; CANCER COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SOFT TISSUE CARCINOMA; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TREATMENT DURATION; UTERINE LEIOMYOSARCOMA;

EID: 79957793286     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq608     Document Type: Review

References (61)

1. Clark MA, Fischer C, Judson I, Thomas JM. Soft-tissue sarcoma in adults. N Engl J Med 2005; 353: 701-711.
2. Karavisilis V, Seddon BM, Ashley S. et al. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer 2008; 112: 1585-1591.
3. Van Oosterom AT, Verweij J. New drugs for the treatment of sarcoma. Hematol Oncol Clin North Am 1995; 9: 909-925.
4. Van Glabbeke M, Verweij J, Judson I. et al. Progression-free rate as the primary endpoint for phase II study in soft tissue sarcoma. Eur J Cancer 2002; 38: 543-549.
5. Adjei AA, Christian M, Ivy P. Novel designs and end points for phase II trials. Clin Cancer Res 2009; 15: 1866-1872.
6. Blay JY, Judson I, Rodenhuis S. et al. Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens. Anticancer Drugs 1999; 10: 873-877.
7. Bramwell VH, Morris D, Ernst DS. et al. Safety and efficacy of the multidrugresistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. Clin Cancer Res 2002; 8: 383-393.
8. Brockstein B, Samuels B, Humerickhouse R. et al. Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer. Invest New Drugs 2001; 19: 249-254.
9. Demetri GD, Chawla SP, Van Mehren M. et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27: 4188-4196.
10. Ferraresi V, Ciccarese M, Cercato MC. et al. Gemcitabine at fixed dose-rate in patients with advanced soft tissue sarcomas: a mono-institutional phase II study. Cancer Chemother Pharmacol 2008; 63: 149-155.
11. Garcia-Carbonero R, Supko JG, Manola J. et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004; 22: 1480-1490.
12. Hartmann JT, Oechsle K, Huober J. et al. An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Invest New Drugs 2006; 24: 249-253.
13. Hartmann JT, Mayer F, Scleicher J. et al. Bendamustine hydrochloride in patients with refractory soft tissue sarcoma.a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001). Cancer 2007; 110: 861-866.
14. Hensley ML, Sill MW, Scribner DR. et al. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol 2009; 115: 460-465.
15. Hensley ML, Blessing JA, DeGeest K. et al. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gyncol Oncol 2008; 109: 23-28.
16. Heymach JV, Desai J, Manola J. et al. Phase II study of antiangionic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res 2004; 10: 5732-5740.
17. Kollmannsberger C, Brugger W, Hartmann JT. et al. Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic softtissue sarcoma. Anticancer Drugs 1999; 10: 453-456.
18. Köstler WJ, Brodowicz T, Attems Y. et al. Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. Ann Oncol 2001; 12: 1281-1288.
19. Kuenen BC, Tabernero J, Baselga J. et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res 2003; 9: 1648-1655.
20. Leahy M, Ray-Coquard I, Verweij J. et al. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2007; 43: 308-315.
21. Le Cesne A, Blay JY, Judson I. et al. Phase II study of ET-743 in advanced soft tissue sarcoma: a European Organization for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trial. J Clin Oncol 2005; 23: 576-584.
22. Look KY, Sandler A, Blessing JA. et al. Phase trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study. Gynecol Oncol 2004; 92: 644-647.
23. Losa R, Fra J, Lopez-Pousa A. et al. Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. Cancer Chemother Pharmacol 2007; 59: 251-259.
24. McMeekin DS, Sill MW, Darcy KM. et al. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study. Gyncol Oncol 2007; 106: 596-603.
25. Merimsky O, Meller I, Flusser G. et al. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol 2000; 45: 177-181.
26. Patel S, Keohan ML, Saif MW. et al. Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy. Cancer 2006; 107: 2881-2887.
27. Ray-Coquard I, Le Cesne A, Whelan J. et al. A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. Oncologist 2008; 13: 467-473.
28. Reichardt P, Oechsle K, Pink D. et al. An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma. Invest New Drugs 2003; 21: 481-486.
29. Sleijfer S, Ray-Coquard I, Papai Z. et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). J Clin Oncol 2009; 27: 3126-3132.
30. Späth-Schwalbe E, Genvresse I, Koschuth A. et al. Phase II trial of gemcitabine with pretreated advanced soft tissue sarcomas. Anticancer Drugs 2000; 11: 325-329.
31. Toma S, Tucci A, Villani G. et al. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG). Anticancer Res 2000; 20: 485-491.
32. Reichardt P, Nielsen OS, Bauer S. et al. Exetecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II-study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2007; 43: 1017-1022.
33. Svancarova L, Blay JY, Judson I. et al. Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft tissue and Bone Sarcoma Group. Eur J Cancer 2002; 38: 556-559.
34. Van Oosterom AT, Mouridsen HT, Nielsen OS. et al. Results of randomized studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 2002; 38: 2397-2406.
35. Verweij J, Lee SM, Ruka W. et al. Randomized phase II study of docetaxel versus doxorubicin in first-line and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000; 18: 2081-2086.
36. ®, Gleever™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: results from the EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003; 39: 2006-2011.
37. Woll PJ, Judson I, Lee SM. et al. Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft tissue and Bone Sarcoma Group. Eur J Cancer 1999; 35: 410-412.
38. Yovine A, Riofrio M, Blay JY. et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004; 22: 890-899.
39. Garcia-Del Muro X, Lopez-Pousa A, Martin J. et al. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma. A study by the Spanish Group for Research on Sarcomas. Cancer 2005; 104: 1706-1712.
40. Baker LH, Rowinsky EK, Mendelson D. et al. A randomized, phase II study of thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J Clin Oncol 2008; 26: 5583-5588.
41. Bailey HH, Mahoney MR, Ettinger DS. et al. Phase II study of oral perifosine in patients with advanced soft tissue sarcoma. Cancer 2006; 107: 2462-2467.
42. Chugh R, Wathen JK, Maki RG. et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a Bayesian hierarchical statistical model. J Clin Oncol 2009; 27: 3148-3153.
43. Debrock G, Vahentenrijk V, Sciot R. et al. A phase II with rosiglitazone in liposarcoma patients. Br J Cancer 2003; 89: 1409-1412.
44. Dileo P, Morgan JA, Zahrieh D. et al. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas. Cancer 2007; 109: 1863-1869.
45. George S, Merriam P, Maki RG. et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumors sarcomas. J Clin Oncol 2009; 27: 3154-3160.
46. Hensley ML, Maki RG, Venkatraman E. et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002; 20: 2824-2831.
47. Maki RG, Kraft AS, Scheu K. et al. A multicenter phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer 2005; 103: 1431-1438.
48. Maki RG, Wathen JK, Patel RS. et al. Randomized phase II study of gemcitabine an docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 2007; 25: 2755-2763.
49. Maki RG, D'Adamo DR, Keohan ML. et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009; 27: 3133-3140.
50. Morris DG, Bramwell VHC, Turcotte R. et al. A phase II study of flavopiridol in patients with previously untreated advanced soft tissue sarcoma. Sarcoma 2006; 6437: 1-7.
51. Okuno S, Ryan LM, Edmonson JH. et al. Phase II trial of gemcitabine in patients with advanced sarcomas (E1797). A trial of the Eastern Cooperative Oncology Group. Cancer 2003; 97: 1969-1973.
52. Patel RS, Beach J, Papadoulos N. et al. Results of a 2-arm phase II of 9-nitrocampothecin in patients with advanced soft tissue sarcomas. Cancer 2003; 97: 2848-2852.
53. Penel N, Binh NB, Bay JO. et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. J Clin Oncol 2008; 26: 5269-5274.
54. Pivot X, Chevreau C, Cupissol D. et al. Phase II trial of paclitaxel-epirubicin in patients with recurrent soft-tissue sarcoma. Am J Clin Oncol 2002; 25: 561-564.
55. Ryan CW, Dolan ME, Brockstein BB. et al. A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemother Pharmacol 2006; 58: 634-639.
56. Talbot SM, Keohan ML, Hesdorfler M. et al. A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. Cancer 2003; 98: 1942-1946.
57. Trent C, Beach J, Burgess MA. et al. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumours and other soft tissue sarcomas. Cancer 2003; 98: 2693-2699.
58. Von Mehren M, Balcerzak SP, Kraft AS. et al. Phase II trial of dolastatin-10, a novel antitubulin agent, in metastatic soft tissue sarcomas. Sarcoma 2004; 8: 107-111.
59. Penel N, Adenis A. Publication biases and phase II trials investigating anticancer targeted therapies. Invest New Drugs 2009; 27: 287-288.
60. Verweij J. Other endpoints in screening studies for soft tissue sarcomas. Oncologist 2008; 13: 27-31.
61. Therasse P, Arbuck SG, Eisenhauer EA. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.